ProShares UltraShort Nasdaq Biotech (BIS)
20.79
+0.70
(+3.48%)
USD |
NASDAQ |
Apr 25, 13:27
Price Chart
Key Stats
Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
0.95% | 0.16% | 3.432M | 8556.50 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
2.28% | -- | -2.648M | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | -- |
Fixed Income Style | -- |
Broad Asset Class | Miscellaneous |
Broad Category | Miscellaneous |
Category Name | Trading--Inverse Equity |
Category Index | S&P 500 TR USD |
Global Category Name | Trading Tools |
YCharts Categorization | Other |
YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
Prospectus Objective | Specialty - Technology |
Fund Owner Firm Name | ProShares |
Prospectus Benchmark Index | |
NASDAQ Biotechnology TR USD | -200.0% |
Broad Asset Class Benchmark Index | |
^SPXTR | 100.0% |
Manager Tenure | |
Michael Neches | 10.51 yrs |
Tarak Davé | 5.93 yrs |
Performance Versus Category
As of April 24, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 24, 2024.
Basic Info
Investment Strategy | |
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | -- |
Fixed Income Style | -- |
Broad Asset Class | Miscellaneous |
Broad Category | Miscellaneous |
Category Name | Trading--Inverse Equity |
Category Index | S&P 500 TR USD |
Global Category Name | Trading Tools |
YCharts Categorization | Other |
YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
Prospectus Objective | Specialty - Technology |
Fund Owner Firm Name | ProShares |
Prospectus Benchmark Index | |
NASDAQ Biotechnology TR USD | -200.0% |
Broad Asset Class Benchmark Index | |
^SPXTR | 100.0% |
Manager Tenure | |
Michael Neches | 10.51 yrs |
Tarak Davé | 5.93 yrs |